ArticleScientific reports2025
Characterisation of gut microbiota in Malaysian cancer patients using V3-V4 region of 16S rRNA gene sequencing.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Stemness-associated MEF-derived extruded nanovesicles cooperate withNanoscale advances · 2026Article
- Immunotherapy in Asia: current insights and prospects in Southeast Asia and Malaysia.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies suggested a potential connection between gut microbiota changes and cancer onset. However, conflicting results make it challenging to understand the role of gut microbiota dysbiosis in cancer, particularly in underrepresented populations like those in Southeast Asia. To address this gap, we analysed the diversity and composition of gut microbiota in 65 faecal samples, which included 48 from cancer patients with various malignancies and 17 from healthy controls. Patients were categorised into four groups: symptomatic patients undergoing cancer treatment, asymptomatic pre-treatment and during cancer treatment, and healthy controls. Genomic DNA was extracted, and the V3-V4 region of the 16 S rRNA gene was sequenced. Our findings revealed significant differences in the alpha diversity (p ≤ 0.05) between cancer patients and controls. Asymptomatic patients under treatment showed slightly lower alpha diversity than pre-treatment patients, but this difference was not statistically significant (p = 0.06). We identified 13 genera with over 20% difference in abundance between patient groups and controls. Asymptomatic patients receiving treatment and pre-treatment patients exhibited enrichment in Enterococcus, whereas Prevotella, Faecalibacterium, Brevundimonas, and Pseudomonas were significantly reduced compared to controls. Symptomatic patients had higher levels of Enterococcus and Staphylococcus, while Ruminococcus was enriched in asymptomatic patients. These underscore the distinct differences in gut microbiota composition between cancer patients and healthy individuals, particularly in symptomatic cases with potential biomarkers such as Enterococcus, Prevotella, and Faecalibacterium. Our study suggests that cancer treatment may not significantly alter the gut profile of cancer patients. Further research is needed to comprehend the implications of these findings fully.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.